Theranexus SA (DE:3VG)
FRANKFURT:3VG
3VG Stock Chart & Stats
€2.74
-€0.06(-8.12%)
At close: 4:00 PM EST
€2.74
-€0.06(-8.12%)
Day’s Range― - ―
52-Week Range€0.70 - €4.31
Previous CloseN/A
Volume0.00
Average Volume (3M)596.00
Market Cap
€45.84M
Enterprise Value€37.37M
Total Cash (Recent Filing)€7.77M
Total Debt (Recent Filing)€2.88M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume242
30 Day Avg. Volume596
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS / Rare-disease FocusA sustained focus on CNS and rare neurological diseases creates durable product-market fit where unmet need, regulatory incentives and pricing power are stronger. Specialized expertise supports differentiated R&D programs and increases the chance of orphan designations and partner interest over the medium term.
Partnership-driven Development ModelLeveraging external partnerships to advance clinical programs reduces sole-company capital requirements and shares development risk. Durable benefits include access to partner expertise, milestone funding and commercialization channels, improving runway and de-risking late-stage development relative to going it alone.
Reduced Leverage And Improving Cash Burn TrendLower absolute debt and evident improvement in operating/free cash flow trends signal incremental stabilization of the balance sheet. Sustained reduction in cash burn and contained leverage increase financial flexibility, extending runway and reducing frequency/size of dilutive financings if maintained over coming quarters.
Bears Say
Persistent Loss-making OperationsChronic negative profitability undermines internal capital generation and forces reliance on external financing. Over the medium term this raises dilution risk, limits ability to self-fund trials or commercialization, and can constrain strategic options such as in-licensing or scaling operations without partner support.
Highly Unstable Revenue; Zero Revenue In 2025A collapse to zero reported revenue in 2025 exemplifies severe revenue visibility issues and likely program or contract discontinuities. This structural instability makes forecasting, securing non-dilutive financing, and planning long-term operations difficult, increasing execution and counterparty risk.
Fragile Equity And Balance-sheet WeaknessHistoric negative equity reflects accumulated losses and prior dilution, reducing borrowing capacity and investor confidence. A fragile balance sheet constrains strategic flexibility, may force unfavorable financing terms, and leaves the company vulnerable to setbacks during clinical development or market shifts.
Theranexus SA News
3VG FAQ
What was Theranexus SA’s price range in the past 12 months?
Theranexus SA lowest stock price was €0.70 and its highest was €4.31 in the past 12 months.
What is Theranexus SA’s market cap?
Theranexus SA’s market cap is €45.84M.
When is Theranexus SA’s upcoming earnings report date?
Theranexus SA’s upcoming earnings report date is Sep 24, 2026 which is in 103 days.
How were Theranexus SA’s earnings last quarter?
Currently, no data Available
Is Theranexus SA overvalued?
According to Wall Street analysts Theranexus SA’s price is currently Overvalued.
Does Theranexus SA pay dividends?
Theranexus SA does not currently pay dividends.
What is Theranexus SA’s EPS estimate?
Theranexus SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theranexus SA have?
Theranexus SA has 14,472,778 shares outstanding.
What happened to Theranexus SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Theranexus SA?
Currently, no hedge funds are holding shares in DE:3VG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theranexus SA
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Technical Analysis
GenSight Biologics SA
―
AB Science SA
―
Sensorion SAS
―
Intrasense SA
―
MedinCell SA
―
Options Prices
Currently, No data available
---